Latest News & Features
article
With the pharmaceutical and biotechnology industry constantly evolving, new and complex therapies are being introduced which challenge the current limitations within patentability. In order for these new innovations to be well protected the patenting process must evolve too. 14 January 2021
Americas
Two federal agencies in the US have agreed to share confidential business information about the manufacture of chemicals that are produced and imported, in efforts to improve the protection of workers who may be exposed to a new chemical substance. 14 January 2021
Americas
Illumina tried to secure its control over the DNA sequencing technology market by violating antitrust law, according to a suit by BGI Americas and two of its subsidiaries, at the US Court for the District Court of San Francisco. 12 January 2021
Big Pharma
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field. 12 January 2021
Americas
The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid. 11 January 2021
Americas
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible. 8 January 2021
Americas
Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew. 7 January 2021
Americas
Chemical manufacturers have a renewed opportunity to protect the confidentiality of the chemicals they make or import, according to an announcement by the US Environmental Protection Agency. 7 January 2021
Big Pharma
A licensing pathway that will reduce the time it takes for novel medicines to enter the marketplace has been launched by the UK Medicines and Healthcare products Regulatory Agency. 7 January 2021
article
There is an increasing area of convergence between high-tech AI and Life Sciences leading to some interesting developments in the administration of IP. So, what does this mean for IP portfolio strategy? 7 January 2021